About CLS Investment Criteria Our Team Scientific Advisors Portfolio News Contact
 
 
     
 

XLumena Spots $6M For Ultrasound Devices
June 4, 2008


Mirabilis Completes First Human Trial of Non-Invasive Treatment for Uterine Fibroids
APRIL 28, 2008


Astellas and CoMentis Sign Agreement to Collaborate on the Research, Development and Commercialization of Beta-Secretase Inhibitors
APRIL 25, 2008


EnteroMedics Announces Planned Expansion of EMPOWER Pivotal Study for Obesity to 300 Patients
February 26, 2008


KFx Medical Corporation Appoints Matt Meyer as its Vice President Marketing
February 20, 2008


EnteroMedics(TM) Announces Nine-Month Clinical Results on Its VBLOC-RF2 Feasibility Study for Obesity Therapy
January 8, 2008


EnteroMedics(TM) Announces Pivotal Clinical Study of its VBLOC(TM) Therapy for Obesity
January 7, 2008


CoMentis Announces Proof-of-Activity-Data from its Phase I Study of Disease-Modifying Alzheimer’s Disease Therapy
January 7, 2008


APT Pharmaceuticals Expands Management Team
NOVEMBER 19, 2007


EnteroMedics Announces Initial Public Offering
NOVEMBER 14, 2007


APT Pharmaceuticals Closes New $22 Million Funding Round
OCTOBER 4, 2007


JDRF Partners with CoMentis for Diabetic Macular Edema Clinical Trial
SEPTEMBER 20, 2007


Mirabilis Closes $10.5 Million Series A Extension to Commercialize Non-invasive Treatment of Uterine Fibroids
AUGUST 21, 2007


KFx Medical Corporation Closes $10 Million Series B Financing
AUGUST 9, 2007


JDRF Partners with CoMentis for Diabetic Macular Edema Clinical Trial
JUNE 18, 2007


CoMentis Announces Appointment of Martin Tolar, M.D., Ph.D., as Vice President
JUNE 6, 2007


APT Acquires Exclusive Worldwide Rights to Develop and Commercialize Inhalable Cyclosporine to Prevent Lung Transplant Rejection
JUNE 5, 2007


Enteromedics Files Registration Statement
for Proposed Initial Public Offering
MAY 25, 2007


CoMentis Initiates Phase II Clinical Trial for AMD Eye Drop Therapy
APRIL 10, 2007


Athenagen Announces Name Change to CoMentis
FEBRUARY 10, 2007


Athenagen’s Eye Drop Therapy for AMD is Safe and Well Tolerated in Phase I Study
JANUARY 31, 2007


Athenagen Initiates Phase II Clinical Trial in Alzheimer’s Disease
DECEMBER 13, 2006


Mirabilis Medica Names Mike Connolly CEO
OCTOBER 3, 2006


Athenagen Raises $50 Million in Series B Financing
SEPTEMBER 28, 2006


Amaranth Medical Closes $7.5 Million Series A Financing to Advance the Development of Bio-Absorbable Stents
SEPTEMBER 26, 2006


Mirabilis Raises $4 Million to Commercialize Non-Invasive Treatment of Uterine Fibroids
AUGUST 29, 2006


Athenagen Initiates Clinical Development of its Anti-angiogenic Eye Drop Therapy for AMD
AUGUST 21, 2006


Athenagen Completes Merger with Zapaq
AUGUST 14, 2006


KFx Medical Corporation Receives 510k Clearance for Knotless Tissue Fixation
AUGUST 10, 2006


Athenagen Announces Publication of Results from a Proof-of-Concept Trial of its Novel alpha-7 Nicontinic Receptor Agonist in Schizophrenia
JUNE 15, 2006


Athenagen Acquires Osprey Pharmaceutical Company - Adds Clinical-Stage Alzheimer's Drug Candidate to its Pipeline
APRIL 13, 2006


Aradigm and APT Pharmaceuticals Initiate Phase 2 Clinical Program of Novel Treatment for Asthma
MARCH 23, 2006


Athenagen Adds A. Barr Dolan to its Board of Directors
FEBRUARY 22, 2006


Previous News Stories >

 
     
 

APT Acquires Exclusive Worldwide Rights to Develop and Commercialize Inhalable Cyclosporine to Prevent Lung Transplant Rejection

Such a Product Should Increase Survival Odds for 1,500 Lung Transplant Patients Annually if Drug is Approved by the FDA

FOSTER CITY, CA – JUNE 5, 2007

APT, a specialty drug development company focused on effective treatments for significant unmet medical needs, announced today that it has entered into an exclusive licensing agreement with Novartis Pharma AG for the worldwide rights to develop and commercialize an inhalable form of cyclosporine for the prevention and treatment of lung transplant rejection.
Cyclosporine, marketed as Neoral®, is an immunosuppressant developed by Novartis for the prevention of organ rejection following kidney, liver or heart transplantation. In late 2004, Chiron Corporation (now Novartis Vaccines and Diagnostics, Inc) submitted a new drug application for an aerosolizable form of cyclosporine to the Food and Drug Administration. The FDA issued an approvable letter in June 2005, opening the door for eventual approval of inhalable cyclosporine.

 
APT Licenses Inhalable Cyclosporine
APT specializes in re-purposing existing drugs, with particular interest in developing new treatments for rare diseases and unmet medical needs. If inhalable cyclosporine is approved by the FDA, it is eligible to receive orphan drug designation, giving APT seven years of exclusivity to market the drug.

“We are delighted to add inhalable cyclosporine to our development portfolio,” said Dr. Stephen Dilly, President and CEO of APT and formerly Chief Medical Officer of Chiron BioPharmaceuticals. “inhalable cyclosporine is an excellent fit with our mission to develop effective treatments to address significant unmet medical needs. Furthermore, as cyclosporine has been used in other transplant indications for 20 years, it is well aligned with our focus on improving well-characterized drugs.”

Under the terms of the Agreement, Novartis has licensed patent, know-how and regulatory cross-referral rights to APT for inhalable cyclosporine.
About 1500 lung transplants are performed in the United States each year. Recipients of lung transplants have a five-year survival rate of about 47% compared to five-year survival rates approaching 85% for heart, kidney and liver transplants. Obliterative bronchiolitis is reported as a cause of death over the long term in about 30% of lung transplant recipients related to chronic rejection from within the airway of the transplanted lung.

Obliterative bronchiolitis often cannot be completely controlled with conventional systemic immunosuppressive therapy as drug levels achieved in the airway are too low and doses are limited by renal and hepatic toxicity. By delivering cyclosporine by inhalation, higher drug levels can be achieved in the airway without significantly increasing circulating drug levels.

 

About the Promise of inhalable Cyclosporine
A long-term study of inhalable cyclosporine, was conducted in 56 lung transplant recipients at the University of Pittsburgh Medical Center, a nationally recognized transplant center, and published in the New England Journal of Medicine in 2006. Patients that received inhalable cyclosporine in addition to their standard immunosuppressive treatment showed a 78% reduction in mortality compared to those in the control group, who received conventional immunosuppressive treatments.

“An inhalable form of cyclosporine is a product that the University of Pittsburgh has worked on for several years and we believe that it provides significant benefit to lung transplant patients,” said Dr. Joseph Pilewski, Medical Director of the Lung transplant Program at the University of Pittsburgh Medical Center. “We are very excited that APT is dedicating the majority of its focus to develop a well-tolerated and user-friendly form of this important and effective immunosuppressant.”

 

About APT Pharmaceuticals, Inc.
APT Pharmaceuticals, Inc. is a drug development company based in Foster City, California. APT is backed by several leading venture capital firms, including Charter Life Sciences, VIVO Ventures and Research Corporation Technologies.

 

For more information: www.aptbio.com.

 

CONTACT:
Ted Rossman/Lisa Kelaita
New Venture Communications
(650) 343-2735
trossman@newventurecom.com
lkelaita@newventurecom.com

 

 
     
     
     
     
   
 
 
© 2006 CHARTER LIFE SCIENCES